Stockreport

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
PDF Estimated 23 million annual agitation episodes in the at-home setting 1-3  No FDA-approved therapies in the at-home setting for acute treatment of agitation associated [Read more]